![]() |
![]() |
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
(51) | INT.CL. | A61K 39/395 | (2006.01) |
A61K 39/3955 | (2013.01) | ||
A61K 31/407 | (2006.01) | ||
A61K 31/495 | (2013.01) | ||
A61K 31/495 | (2006.01) | ||
C07K 16/22 | (2013.01) | ||
C07K 16/2896 | (2013.01) | ||
A61P 35/00 | (2006.01) | ||
A61P 35/02 | (2006.01) | ||
C07K2317/21 | (2013.01) | ||
C07K2317/24 | (2013.01) | ||
C07K2317/73 | (2013.01) | ||
A61K 31/407 | (2013.01) | ||
A61K2039/545 | (2013.01) | ||
A61N2005/1098 | (2013.01) | ||
A61P 35/00 | (2018.01) | ||
A61P 35/02 | (2018.01) |
(11) | Patento numeris | 3463458 |
(13) | Dokumento rūšis | T |
(96) | Europos patento paraiškos numeris | 17730628.9 |
Europos patento paraiškos padavimo data | 2017-06-01 | |
(97) | Europos patento paraiškos paskelbimo data | 2019-04-10 |
(45) | Paskelbimo apie Europos patento išdavimą data | 2024-04-10 |
(46) | Apibrėžties vertimo paskelbimo data |
(86) | Numeris | PCT/US2017/035504 |
Data | 2017-06-01 |
(87) | Numeris | WO 2017/210463 |
Data | 2017-12-07 |
(30) | Numeris | Data | Šalis |
201662344194 P | 2016-06-01 | US | |
201662349491 P | 2016-06-13 | US | |
201662362845 P | 2016-07-15 | US | |
201662374136 P | 2016-08-12 | US | |
201662418466 P | 2016-11-07 | US | |
201662424178 P | 2016-11-18 | US | |
201762471321 P | 2017-03-14 | US | |
201762490528 P | 2017-04-26 | US | |
201762491943 P | 2017-04-28 | US |
(72) |
TRIKHA, Mohit , US
LEVIN, Nancy , US
MACLAREN, Ann , US
|
(73) |
Celgene Tri A Holdings Ltd. ,
Aon House 30 Woodbourne Avenue, Pembroke HM 08,
BM
Trikha, Mohit , 3366 N. Torrey Pines Court 210, La Jolla, California 92037, US Levin, Nancy , 3366 N. Torrey Pines Court 210, La Jolla, California 92037, US Maclaren, Ann , 3366 N. Torrey Pines Court 210, La Jolla, California 92037, US |
(54) | COMBINED USE OF MARIZOMIB AND BEVACIZUMAB FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) CANCERS |
COMBINED USE OF MARIZOMIB AND BEVACIZUMAB FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) CANCERS |